Manufacturing Process of SER-109, a Purified Investigational Microbiome Therapeutic, Reduces Risk of Coronavirus Transmission From Donor Stool

por McChalicher, Christopher, Abdulaziz, Ahmad, Zhou, S Steve, Lombardo, Mary-Jane, Hasson, Brooke, Auniņš, John G, McGovern, Barbara H, Ege, David S
Publicado 2022

1035. Manufacturing Processes of SER-109, a Purified Investigational Microbiome Therapeutic, Reduce Risk of Transmission of Emerging and Undetected Infections in Donor Stool

por McChalicher, Christopher, Abdulaziz, Ahmad, Halvorsen, Elizabeth, Lombardo, Mary-Jane, Winkler, Jonathan, Almomani, Sanabel, McGovern, Barbara, McKenzie, Gregory, Ege, David, Aunins, John
Publicado 2021

Manufacturing Processes of a Purified Microbiome Therapeutic Reduce Risk of Transmission of Potential Bacterial Pathogens in Donor Stool

por McChalicher, Christopher W J, Lombardo, Mary-Jane, Khanna, Sahil, McKenzie, Gregory J, Halvorsen, Elizabeth M, Almomani, Sanabel, Schuster, Brian, Hasson, Brooke R, McGovern, Barbara H, Ege, David S, Auniņš, John G
Publicado 2023

SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent Clostridioides difficile Infection (rCDI)

por Khanna, Sahil, Sims, Matthew, Louie, Thomas J., Fischer, Monika, LaPlante, Kerry, Allegretti, Jessica, Hasson, Brooke R., Fonte, Allyson T., McChalicher, Christopher, Ege, David S., Bryant, Jessica A., Straub, Timothy J., Ford, Christopher B., Henn, Matthew R., Wang, Elaine E. L., von Moltke, Lisa, Wilcox, Mark H.
Publicado 2022